MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HICl, FOXSl, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DUGAST-DARZACQ, CLAIRE, NOIZET, MAÏTÉ, DARZACQ, XAVIER
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HICl, FOXSl, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2. La présente invention concerne un composé thérapeutique comprenant : un agent qui inhibe l'activité d'au moins un gène sélectionné dans le groupe constitué par HICl, FOXSl, CREB5, IRF7, POU2F2, STAT4 et TCF4 et/ou un agent qui renforce l'activité d'au moins un gène sélectionné dans le groupe constitué par MAF, MEOX2 et SIX2.